


Regenerative Medicine Scholarly Pathway 2026



Course Director:
Lina Shehadeh, PhD

Regenerative Medicine Scholarly Pathway Course

03/24/26 through 05/19/26

Course Module Director: Lina Shehadeh, PhD

I. Introduction

The faculty involved with the teachings of the Regenerative Medicine Scholarly Pathway Course want to welcome you to the next seven weeks of stimulating learning. This marks a major transition in your medical education! The Regenerative Medicine Scholarly Pathway is one of 13 scholarly pathways that NextGen medical students get the chance to enroll in and pursue as a research track during their entire medical education journey. Our primary goals are for you to develop a strong foundation of regenerative medicine and develop a research knowledge base that allows you to understand and appreciate related research articles and enroll in a UM research laboratory and perform cutting edge research under the mentorship of one of our best regenerative medicine faculty.

II. Course Description

The structure of the regenerative medicine scholarly pathway course allows the students to develop a basic understanding of the evolution of regenerative medicine and its application to vast variety of diseases. Importantly, the structure of the course will help the students understand and discuss research on stem cell application. Attendance and participation is required for all 9 sessions as this is the best opportunity to solidify your self-directed learning and of course ask questions. Multiple faculty members from different disciplines and subspecialties will be involved in these teachings. We plan to record all the zoom sessions. Specific objectives for all teaching activities are clearly stated in this syllabus along with supplemental content and reading material.

Content Flow

This course is 9 sessions in total that aims to meet the learning goals on 1) Gene Therapy, 2) Cell Transplantation, 3) Transplantation Immunology, and Induced Pluripotent Stem Cells (iPSCs) – each detailed below under Course Objectives. Throughout the course, we will discuss a group of research articles that are focused on lentiviral gene therapy using hematopoietic stem cells (HSCs) for treatment of sickle cell disease (SCD). This is a fascinating story from bench to bedside with successes in clinical trials and a most recent 2021 halt on the trials because of a suspected leukemia side effect. The distribution of the student presentation will be throughout the course to make these discussions integrated with the teaching material presented by the faculty. Also, throughout the course, the students will work on their other assignments listed below.

Dr. Shehadeh will be available throughout the course to help you stay oriented and direct you when necessary. We can have a class representative to establish effective and accurate communications throughout the course. The faculty involved in the teaching of the course and the research mentors (listed in the faculty roster below) are available to

discuss your interests and answer questions. Please reach out to them by email and you can schedule 1:1 meeting with them.

III. **Research Articles and Presentations**

The theme of the research articles studied and discussed in this course will be on lentiviral gene therapy using hematopoietic stem cells (HSCs) for treatment of sickle cell disease (SCD). This is a fascinating story from bench to bedside with successes in clinical trials and a most recent 2021 halt on the trials because of a suspected leukemia side effect. **Eight research papers are posted on Blackboard** and will be used for article discussions and presentations.

IV. **Interview with a Physician Scientist**

Each student will interview one of our successful physician scientists at UM and present the interview to the class. The goal of this activity is to learn from the various experiences of UM physician scientists who can be role models for the MD students. After planning with Dr. Shehadeh, each student will reach out to the physician scientist and schedule the date of the interview and the date of presenting to the class.

V. **Stock Market Analysis of a Regenerative Medicine Company**

The goal of this exercise is to understand the link between science, discoveries, publications, clinical trials on one hand and the value of regenerative medicine companies on the stock market on the other hand. After planning with Dr. Shehadeh, each student will choose one pharmaceutical company and summarize to the group its history and value in relation to preclinical and clinical studies.

VI. Scholarly project proposal: The culmination of this course will be the development of a scholarly project proposal that states the scholarly (research) question that will be examined in the mentoring project, and an outline of the scholarly project activities that will take place in June – July 2026. Pathways may specify a more detailed format, but the general format will be a 1-page background section that contains a statement of the scholarly question, and a 1–2-page outline of the components of the scholarly project plan (organized as specific aims, deliverables or milestones, or project components or elements, depending on the discipline of study). The pathway director and mentor will evaluate the sufficiency of this proposal. A general rubric for the evaluation is provided on Blackboard.

At the end of the course, students who performed less than satisfactorily will be notified in **TWO WAYS**. Each student will receive a letter signed by the coordinators with a copy sent to Dean Chrisfouad Alabiad. Each student will also be notified by the student e-mail address. These students are then **required** to notify Dr. Shehadeh, by e-mail at lshehadeh@miami.edu. A meeting will be scheduled with Dr. Shehadeh to discuss options.

VII. Nine SESSIONS:

There are **nine mandatory** sessions during the 9-week module. The schedule shown below is updated in Blackboard with room numbers and zoom links. **Please use Blackboard as the most updated version of the schedule.**

These sessions consist of some lectures and small group sessions. These 9 sessions are listed below and will be labeled mandatory on the posted schedule. They are all via zoom except for the one by Dr. Levy which will be in person (location will be sent). The plan is to record all the zoom sessions.

All absences, whether excused or unexcused, will be monitored and tracked. Too many could result in a **PIRS**. This includes both excused and unexcused absences. Please refer to the "Medical Student Rights and Responsibilities Handbook 2019 - 2020" pages 12-14 for more information on this.

Nine Sessions

	Date	Time	Title	Faculty	Objectives
Tuesday	3/24/26	2:00-4:00 (Zoom-Recorded)	Introduction to Regenerative Medicine Pathway	Lina Shehadeh, PhD	
Tuesday	3/31/26	2:00-4:00 (Zoom-Recorded)	Research Article Discussion	Lina Shehadeh, PhD	
Tuesday	4/7/26		<i>Spring Break</i>		
Tuesday	4/14/26	2:00-4:00 (Zoom-Recorded)	Research Article Discussion	Lina Shehadeh, PhD	
Tuesday	4/21/26	2:00-4:00 (Zoom-Recorded)	Induced pluripotent stem cells in disease modeling and therapy	Derek Dykxhoorn, PhD	Meet Pathway Goal #4 on iPSCs
Tuesday	4/28/26	2:00-4:00 (Zoom-Recorded)	Cloning and Genomics	Roberto Vazquez-Padron, PhD	Meet Pathway Goal #1 on Gene Therapy and Goal #2 on understanding the biology of adult stem cell senescence
Tuesday	5/5/26	2:00-4:00 (Zoom-Recorded)	Cardiovascular Gene Therapy: Past, Present and Future	Laisel Martinez, PhD	Meet Pathway Goal #1 on Gene Therapy
Tuesday	5/12/26	2:00-4:00 (Zoom-Recorded)	Research Article Discussion/Assignments	Lina Shehadeh, PhD	
Tuesday	5/19/26	2:00-4:00 In Person (Rm TBD)	Application and Regulation of HSC Transplantation	Robert Levy, PhD	

VIII. GRADING:

The final grade is the sum of points earned from the participation, research paper presentation, scholarly project proposal, interview of a physician scientist, and stock market analysis of a regenerative medicine company.

Participation: 3% x 8 sessions = 24%

Research Paper Presentation = 26%

Scholarly Project Proposal = 30%

Interview with a Physician Scientist = 10%

Stock Market Analysis of a Regenerative Medicine Company = 10%

- a) **Passing Grade:** It is anticipated that a **passing grade** for the module will be a **score of 70%**; however, the cutoff point will, of course, depend upon the final grade distribution. The course director will review the distribution of grades and decide regarding the lowest possible passing score for the module.
- b) **Failing Grade:** < 70% (unless adjusted as discussed above)
- c) **D Grades:** Depending upon the final grade distribution, a grade of D may be assigned by the module coordinators to students whose performance is close to a failing grade. This could result in a recommendation for the student to perform remedial work. Unless altered by the class grade distribution, **students scoring 70%-74% will receive a D grade.** The promotions committee will make the final decision regarding this issue.
- d) **Remedial Work:** Permission to perform remedial work and the date for the remediation must be approved by both the course director and the Freshman Promotion Committee.

Any student with special circumstances must meet with the coordinators so appropriate accommodations can be made. The course director needs to know about these special circumstances before missing a deadline.

In the event of a personal emergency, the course director and the Office of Student Affairs must be notified of the absence as soon as possible. Missed deadlines will be rescheduled at the discretion of the course director. Unexcused absences will result in a grade of zero (0) for the missed work.

IX. Syllabus

The syllabus contains the nine-week course schedule, lecture objectives, assignments, reference to papers posted on Blackboard, grade breakdown, course directions when applicable, faculty roster, and the list of available mentors and a short description of their research programs. Pertinent information and handouts will be provided as required on Blackboard. The student is urged to keep up to date with the syllabus.

X. Attendance

Student attendance is mandatory for all 9 interactive sessions. We look forward to these nine weeks of exciting interactions.

From "our heart to yours."
Lina Shehadeh, PhD

Faculty Roster

Includes faculty office locations and phone numbers. Faculty e-mail addresses can be found in the University of Miami Miller School of Medicine's e-mail address book. Students are encouraged to discuss any problems or concerns with the course director and seek out individual faculty if desired.

Faculty	Email	Department	Address
Chunming Dong, MD	cdong3@med.miami.edu	Medicine	BRB 812
Derek Dykxhoorn, PhD	DDykxhoorn@med.miami.edu	Human Genetics	BRB 406
Joshua Hare, MD	jbarrett@miami.edu	Medicine	BRB 910
Robert Levy, PhD	rlevy@med.miami.edu	Microbiology	RMSB 3123A
Lina Shehadeh, PhD	lshehadeh@med.miami.edu	Medicine	BRB 818
Roberto Vazquez-Padron, PhD	rvazquez@med.miami.edu	Surgery	RMSB 1048
Karen Young, MD	KYoung3@med.miami.edu	Pediatrics	BCRI 345
Dimitrios Kouroupis, PhD	dxk504@med.miami.edu	Orthopedics	DRI 3014
Thomas Best, MD, PhD	txb440@med.miami.edu	Orthopedics, Biomedical Engineering	Lennar Foundation Medical Center
Ralf Paus, MD	rxp803@med.miami.edu	Dermatology	
Shelby Burks, MD	sburks@med.miami.edu	Neurological Surgery	UMHS
Laisel Martinez	lmartinez6@med.miami.edu	Surgery	RMSB 1048
Evangelos Badiavas, M.D	ebadiavas@med.miami.edu	Dermatology	BRB
Marjana Tomic-Canic, Ph.D.,	mtcanic@miami.edu	Dermatology	RMSB
Jonathan Schatz, MD	jschatz@med.miami.edu	Medicine	
Keyvan Nouri, MD	knouri@med.miami.edu	Dermatology	

Regenerative Medicine Scholarly Pathway Course Objectives

Pathway Goals:

#1 Gene Therapy

After the course, the students should be able to:

1. Explain mechanisms that are involved in viral gene integration in mammalian cells.
2. Apply their knowledge in molecular biology to genetic modification of mammalian cells. This means they should be able to develop cloning strategies for your gene of interest into a viral vector and propose a strategy for *in vivo* genetic manipulation.
3. Apply their knowledge in single gene disorders and develop treatment schemes for patients with these disorders using gene therapy.

#2 Cell Transplantation

After the course, the students will be able to:

1. Describe the basics of stem cell biology, different types of stem cells and the immunological mechanisms behind engraftment and rejection, and how tolerance develops after transplantation.
2. Extract and integrate information from state-of-the-art lectures in combination with overview articles and literature searches on the internet within the research field.

#3 Transplantation Immunology

After the course, the students are expected to be able to:

1. Discuss immunological principles of relevance to transplantation and relate those to normal immunological reactions.
2. Relate relevant methods used for investigations and diagnosis in relation to stem cell and organ transplantation.
3. Discuss the cutting-edge of preclinical transplantation research.
4. Discuss diagnostic principles before and after transplantation that are under development.
5. Give a historical perspective of clinical and preclinical transplantation.
6. Reflect over the future of clinical transplantation immunology.

#4 Induced Pluripotent Stem Cells (iPSCs)

After the course, the students are expected to be able to understand how:

1. Patient-specific iPSCs, and the differentiated products, can help to better understand pathogenic mechanisms that underlie disease.
2. Patient-specific iPSCs can serve as a source of autologous cells for transplantation therapies.

Introduction to Regenerative Medicine Pathway

Lina Shehadeh, PhD

March 24, 2026

2:00 – 4:00pm

Zoom Session

- A. Go over syllabus.
- B. Meet each other and learn about each other's interests.
- C. Plan paper discussions and presentations.
- D. Plan the interviews and other assignments.
- E. Plan and assign deadlines.
- F. Help identify research mentor and plan pathway research project.
- G. Update on mentor-mentee matches.

Research Article Presentation and Discussion

Lina Shehadeh, PhD

Tuesday March 31, 2026

2:00 – 4:00pm

Zoom Session

Assignment Presentation

Lina Shehadeh, PhD

Tuesday April 14, 2026

2:00 – 4:00pm

Zoom Session

Induced pluripotent stem cells (iPSCs) in disease modeling and therapy

Derek Dykxhoorn, PhD

Tuesday April 21, 2026

2:00 – 4:00pm

Zoom Session

Learning Objectives:

- A. Patient-specific iPSCs, and the differentiated products, can help to better understand pathogenic mechanisms that underlie disease.
- B. Patient-specific iPSCs can serve as a source of autologous cells for transplantation therapy.

Recombinant DNA, Cloning, and Genome Editing in Regenerative Medicine

Roberto Vazquez-Padron, PhD

Tuesday April 28, 2026

2:00 – 4:00pm

Zoom Session

Learning Objectives:

- A. Understand the Fundamentals of Recombinant DNA Technology: Explore the principles of recombinant DNA from a historical perspective and its evolution in biomedical research. Describe key techniques such as restriction enzyme digestion, ligation, and transformation, and their applications in genetic engineering.
- B. Examine Genome Editing Technologies: Introduce CRISPR-Cas9, TALENs, and ZFNs as gene-editing tools. Discuss the mechanisms, advantages, and limitations of each technology in precision medicine and regenerative applications.
- C. Foster Critical Thinking in the Application of Genetic Engineering to Regenerative Medicine: Investigate the role of stem cell modification in biomedical sciences. Assess the potential of gene editing in treating genetic disorders, cardiovascular diseases, and other regenerative applications. Analyze the challenges and opportunities in translating genetic engineering technologies to clinical practice.

Cardiovascular Gene Therapy: Past, Present and Future

Laisel Martinez, PhD

Tuesday May 5, 2026

2:00 – 4:00pm

Zoom Session

Learning Objectives:

- A. Understand the types of gene therapy, targets, and techniques used to deliver it
- B. Learn about the promise, challenges, and risks of gene therapy
- C. Learn how gene therapy fits into the arsenal of preventive or curative treatments for cardiovascular diseases

Assignment Presentation

Lina Shehadeh, PhD

Tuesday May 12, 2026

2:00 – 4:00pm

Zoom Session

Application and Regulation of Hematopoietic Stem Cell (HSC) Transplantation

Robert Levy, PhD

Tuesday May 19, 2026

2:00 – 4:00pm

In-Person

Learning Objectives:

- A. Understand the key differences between allogeneic and autologous hematopoietic stem cell transplants.
- B. Appreciate what defines hematopoietic stem cell transplants as successful.
- C. Understand the contributions from donor cells to functional immunity and anti-tumor responses in recipients post-allo-HSCT.

Assignment Presentation

Lina Shehadeh, PhD

Tuesday May 26, 2026

(backup)

2:00 – 4:00pm

Zoom Session

10 Mentors

(Actually >10 listed in the Table on page 8!)

<https://www.shehadelab.com/scholarly-research-md-students>

1) Chunming Dong, MD



Research Summary:

My research spans from genomics, epigenetics, to molecular and cellular biology, as it relates to cardiovascular disease (CVD). My major focuses are atherosclerosis and the dysfunction of endothelial progenitor cells (EPCs)—a form of stem cells derived from the bone marrow and circulating in the peripheral blood—in the contexts of biological aging, smoking, HIV infection and cocaine abuse. Indeed, I have had multiple Federal and State grants to study the in-depth molecular mechanisms, focusing on microRNAs, underlying EPC dysfunction in aging, smoking and HIV infection. Over the last 5 years, my research has expanded to study the molecular mechanisms that underlie cocaine-induced cardiovascular disease (CVD) using small RNA and RNA sequencing and functional genomics. We are also investigating the use of extracellular vesicles (EVs)/exosomes and EV RNA sequencing to identify EV-microRNA (EV-miR) candidates that predict CVD in people living with HIV (PLHIV) and use EV injections to reconstitute the effects of HIV infection in the cardiovascular system. Furthermore, we have generated tailored EVs that carry modified EV-miR cargo by genetically engineering mesenchymal stromal cells (MSCs) and have successfully used these tailored EVs to treat CVD.

Research Projects:

1. Study the role of plasma EVs in mediating the effects of HIV infection in the development of HIV-associated accelerated CVD and the use of tailored EVs to prevent/treat CVD.
2. Investigate the miRNA-mRNA pathways that regulate the cocaine effects in CVD.
3. Use CRIPR-Cas9 technology to knockout MHC molecules to create universal organs for allograft transplantation

2) Dr. Derek Dykxhoorn, PhD



Research Summary:

Research in the Dykxhoorn laboratory focuses on understanding the molecular and cellular mechanisms that underlie a variety of neurological disorders including neurodevelopmental, neurodegeneration, and sensorineural disorders. To that end, we apply novel stem cell based models of neurons, glial cells, and organoids to study the role of specific genetic variants in disease development. The ultimate goal of these experiments is to identify therapeutic targets that will effectively restore/normalize cellular functional and abrogate the development of these diseases, including the application of high content screening approaches along with genome editing approaches.

Research Projects:

1. Study the role of genetic variants in Alzheimer-associated genetic variants play in disease development.
2. Understand the role of the excitation/inhibition balance in proper neuronal development in autism and epilepsy.
3. Genome engineering and cell-based therapeutic strategies in the treatment of sensorineural hearing loss.

3) Dr. Joshua Hare, MD



Research Summary:

Our goal is to develop better understanding and treatments for heart disease. Our lab utilizes multiple approaches, ranging from cell culture to animal models to clinical trials. We perform mechanistic studies focusing on the cellular and molecular effects of nitric oxide (NO), novel pharmaceutical agents and cell therapy. Our studies revealed that NO influences normal and pathologic cardiac physiology, and signals in a complex manner through interactions between NO and reactive oxygen species, a process termed nitroso-redox balance. We have determined that Growth Hormone Releasing Hormone Receptor agonists have beneficial effects in large and small animal models of myocardial infarction, and we expect to move them into clinical trials in the near future. We have a longstanding interest in the pathophysiology and clinical manifestations of dilated cardiomyopathy (DCM), particularly the role of immunological activation and the microarray/transcriptomic profile of patients as a cause/diagnosis of DCM. Our significant experience with adult stem cells, including induced pluripotent stem cells (iPSCs), spans the gamut from basic research to clinical trials.

Research Projects:

1. Analysis of cardiac structure and function from small and large animal studies, e.g. magnetic resonance imaging, pressure volume loops, echocardiography, histology.
2. Manipulation of iPSCs and analysis of their differentiation into cardiomyocytes.

4) Dr. Robert Levy, PhD



Research Summary

Allogeneic hematopoietic stem cell transplantation (aHSCT) is a potentially curative therapy for a number of hematologic malignancies including acute myeloid leukemia (AML) and relapsed/refractory non-Hodgkin lymphoma (NHL). Unfortunately, graft vs host disease (GVHD) remains a serious clinical problem post-aHSCT which threatens anti-tumor (GVM) immune function and patient survival. As the number of aHSCTs rises, the need for better strategies to treat GVHD, while preserving the GVM response, remains paramount. The Levy lab is developing novel approaches to suppress GVHD while maintaining GVL. Our collaborative work with the Komanduri lab discovered that targeting the MEK pathway using a 3rd generation MEK inhibitor, trametinib specifically inhibits allo-reactive naïve and early memory T cells, while sparing pathogen- and cancer-specific donor T cells critical for GVM post-HSCT (Blood, 2013, PMC3674663; JCI Insight, 2016, PMC5033881). Building on these findings, we recently discovered a novel 2-pathway strategy for FoxP3+ Treg expansion in donors which spares GVM while suppressing GVHD (Biol Blood Marrow Transplant, 2017, PMC5625339 and 2018, PMID: 29751114). Recent work demonstrates their Treg strategy is superior to post-transplant cyclophosphamide (PTCy) for GVHD prophylaxis (JCI Insight, 2018 in revision). Based on the role of STING in modulating anti-tumor immunity, the Levy labs explored the role of STING in promoting the development of GVHD and discovered that GVHD following matched (“MUD”) HSCT is reduced in the absence of STING and worsened using STING agonists suggesting that inhibition of STING in recipient cells can be a novel strategy to reduce GVHD and maintain GVM (Sci Transl Med. 2020 Jul 15;12(552):eaay5006. doi: 10.1126/scitranslmed.aay5006.PMID: 32669421; <https://medicalxpress.com/news/2020-07-sylvester-protein-ease-graft-host.html>.)

Click [here](#) to see 2-slide summary and 7-minute video by Dr. Levy!

5) Dr. S. Shelby Burks, MD



Research Summary

Our lab focuses on severe peripheral nerve injury. We are housed in the Miami Project to Cure Paralysis. Research focuses on the use of Schwann cells and Schwann cell products (exosomes) and their ability to enhance peripheral nerve recovery. We have partnered with industry and federal funding agencies to investigate this in both clinical and preclinical models. Along these lines we are investigating a second generation, three-dimensional nerve conduit which can function as a cell delivery device. In addition to functional recovery we are also evaluating novel pain and sensory outcomes.

Pre-clinical / animal research

1. The use of three-dimensional axon guidance channels to enhance peripheral nerve recovery.
2. Optimization of Schwann cell and Schwann cell products to enhance.
3. Optimization of nerve repair techniques and cellular transplantation strategies to reduce neuropathic pain after injury.

Clinical / human subject research

4. Autologous Schwann cell transplantation in severe peripheral nerve and brachial plexus injury.
5. The use of nerve transfers in cervical spinal cord injury.

Medical students interested in working in our laboratory will work closely with our post-doctoral fellow. Please do not hesitate to reach out to me directly with questions: S. Shelby Burks MD – sburks@med.miami.edu.

<https://scholar.google.com/citations?user=Djq8TR8AAAAJ&hl=en>

6) Dr. Lina A Shehadeh, PhD



Research Summary:

Click [here](#) to check out projects at the Shehadeh Lab.

Research Projects:

1. Screening of FDA-approved drugs to identify best candidates for reducing LDL cholesterol influx. The assay employs Alport patient-derived iPSCs differentiated into renal tubular epithelial cells, and live cell imaging.
2. Screening of FDA-approved drugs to identify best candidates for inducing cardiac regeneration (endogenous adult cardiomyocyte division). The assay employs mosaic analysis with double markers (MADM) mice in which cardiomyocyte division is evidenced by single colored red or green daughter cells.
3. Screening of FDA-approved drugs (and other reagents) to identify best candidates for reducing SARS-Co-V2-spike bearing pseudoviral infection. The assay employs inoculation with pseudovirus in various human cell lines, and live cell imaging.

7) Dr. Roberto I Vazquez-Padron, PhD



Research Summary:

My research focuses on the cellular and molecular mechanisms underlying obstructive vascular diseases like atherosclerosis, in-stent restenosis, transplant vasculopathy, and arteriovenous fistula failure. In particular, my laboratory aims at understanding the role of integrins, tyrosine kinases, and ECM modifying enzymes in the phenotypic switching and growth of constituent cells in arterial and venous walls in response to physiological and pathological cues. The work of my research group involves human studies and cellular and in vivo models. As a basic scientist with many clinical collaborators, my overall goal is to provide a better molecular understanding of these diseases so that improved vascular therapies can be designed.

Research Projects:

1. The role of microbiome in Inflammatory Bowel Disease related atherosclerosis.
2. Catheter infections and vascular diseases
3. The role of Lysyl Oxidase in vascular calcification

8) Dr. Karen Young, MD, MS



Research Summary:

Dr. Young's laboratory is housed in the Batchelor Children's Research Institute. Her lab's primary focus is understanding the molecular and cellular mechanisms that lead to endothelial dysfunction in preterm infants with bronchopulmonary dysplasia (BPD) and pulmonary hypertension (PH). Her **current projects** involve 1) defining the mechanisms by which mesenchymal stem cell cells and their exosomes reduce BPD/PH, 2) elucidating whether endothelial progenitor cell mitochondrial dysfunction is a common major cellular pathway that links neonatal intermittent hypoxia episodes to long-term endothelial dysfunctional states and impaired cardiopulmonary outcomes, 3) defining the role of aging pathways in BPD/PH pathogenesis and 4) understanding the molecular mechanisms that link placental dysfunction to BPD/PH. Over the past 2 decades, Dr. Young has mentored many undergraduates, medical students, residents, and fellows, many of whom have received research awards and themselves become leaders and mentors.

9) Dr. Ralf Paus, MD, DSc, FRSB




Research Summary:

The Paus Lab mainly studies the human hair follicle as a regenerative and reparative model organ, with translational emphasis on the pathobiology, prevention, and therapy of alopecia areata, scarring alopecias, and chemotherapy-induced hair loss and their prevention. Using the organ culture of scalp hair follicles and human scalp as preferred research models, the lab also interrogates mechanisms of human organ and stem cell aging & rejuvenation, and interrogates the impact of neuromediators, chemosensory receptors, and various drugs on hair growth and pigmentation.

Research projects:

- B. Human tissue aging under chemotherapy and its prevention
- C. Melatonin as an anti-aging hormone
- D. Mechanisms of hair greying and its reversal
- E. Neural inputs on human skin aging

10) Dr. Thomas Best, MD, PhD & Dr. Dimitrios Kouroupis, PhD



Research Summary:

ADVANCED STEM CELL TECHNOLOGIES (ASCT) LAB

MAIN GOAL:

The overarching goal of the ASCT lab is to advance cell therapies using adult Mesenchymal Stem Cells (MSC) by addressing key aspects of the manufacturing of a cell-based product. The areas of interest span from processing of the cells to their delivery to the patient, with special attention to the current regulatory concepts from the Food and Drug Administration (FDA) agency. On this basis, our main focus is ‘MSC signatures’ which are directly related to specific MSC functions in vivo for effective musculoskeletal therapeutics, and especially Osteoarthritis.

PROJECTS: We investigate the MSC responses to environmental stimulation & functional subpopulations. On this basis, various projects are directed at understanding how MSC sense their immediate microenvironment and respond molecularly as part of their so-called ‘Medicinal activities’. Specifically:

- Identification and characterization of distinct phenotypic mesenchymal stem cell (MSC) subpopulations within crude preparations isolated from bone marrow (BM), infrapatellar fat pad (IFP), adipose (ASC), umbilical cord (UC) and endometrial (endo) tissues. Secondary to this, to understand how these distinct “signatures” impact their performance as cell progenitors, immunomodulators and trophic effectors during cell-based therapy, developing ex vivo protocols to reduce the innate product heterogeneity by inducing “more uniform” functional phenotypes with specific attributes.
- MSC intercellular communication mechanisms through exosomes-type of extracellular vesicles during immunomodulation and tissue repair, and ways to “tailor” their signaling cargo by processing parental MSC.
- Generation of novel ways to deliver MSC (e.g., 3D structures) that maintain and protect the beneficial induced phenotypic features (anti-inflammatory, anti-fibrotic, analgesic).
- Development of potency assays to predict MSC efficacy ex vivo that result from the identified functional signatures.